Study Reveals Importance Of Timing For Cellular Signals, Suggests Possible Tactic For Cancer Therapeutics
Magic tricks work because they take advantage of the brain’s sensory assumptions, tricking audiences into seeing phantoms or overlooking sleights of hand. Now a team of UC San Francisco researchers has discovered that even brainless single-celled yeast have sensory biases that can be hacked by a carefully engineered illusion, a finding that could be used to develop new approaches to fighting diseases such as cancer.
“The ability to perceive and respond to the environment is a basic attribute of all living organisms, from the greatest to the smallest,” said Wendell Lim, PhD, the study’s senior author. “And so is the susceptibility to misperception. It doesn’t matter if the illusion is based on molecular sensors within a single cell or neurons in the brain.”
In the new study, published online Nov. 19, 2015 in Science Express, Lim and his team discovered that yeast cells falsely perceive a specifically timed pattern of stress – caused by alternating between low and mildly increased sodium levels – as a massive, continuously increasing ramp of stress. In response, the microbes end up over-responding and killing themselves. The results, Lim says, suggest a whole new way of looking at the perceptual abilities of simple cells and could even be used to develop new approaches to fighting diseases using the power of illusion.
Timing of stress response is yeast cells’ ‘Achilles heel’
“This discovery was a bit of an accident actually,” said Lim, chair of the Department of Cellular and Molecular Pharmacology at UCSF, director of the UCSF Center for Systems and Synthetic Biology, and a Howard Hughes Medical Institute (HHMI) investigator. “We were interested in the general issue of how cells interpret information over time. Frequency is a key aspect of all our communications, whether it’s hearing language or transmitting radio signals, but do cells themselves use this kind of information? It’s something we don’t know much about.”
To explore this question, two postdoctoral fellows in Lim’s lab, Ping Wei, PhD, now at Peking University School of Life Sciences, and Amir Mitchell, PhD, set up a system that allowed them to expose yeast to a mild stressor – a small increase in salt in the yeast’s environment – and to oscillate between the increased salt level and the baseline level at different frequencies.
Normally, sensor molecules in a yeast cell detect changes in salt concentration and instruct the cell to respond by producing a protective chemical. After this transient response, the cell can resume growing happily as if conditions had not changed. The researchers found that the cells were perfectly capable of adapting when they flipped the salt stress on and off every minute or every 32 minutes. But to their surprise, when they tried an eight-minute oscillation of precisely the same salt level the cells quickly stopped growing and began to die off.
“That was just a jaw-dropping moment,” said Mitchell. “These cells should be able to handle this level of osmotic stress, but at one particular frequency they just go haywire. We’d never seen anything like this before.”
Could sensory illusions be used to fight cancer?
Mitchell, who was first author on the new study, went on to inspect the cellular mechanism underlying this unexpected, frequency-dependent toxicity. Using mathematical modeling and experiments in which he tweaked the molecular wiring of the mitogen activated protein kinase (MAPK) pathway that mediates the cells’ salt-sensing system, he revealed a sensory misperception: Because of the way the MAPK pathway is set up, the cells interpret an eight-minute oscillation as an ever-increasing staircase of salt concentration. This leads to excessive activation of the cells’ protective response, and ultimately to their death (see Movie).
Read more: Sensory Illusion Causes Cells to Self-Destruct
The Latest on: Cancer Therapeutics
[google_news title=”” keyword=”Cancer Therapeutics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer Therapeutics
- Global Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Poised for Significant Growth, Projected to Reach USD 1593 Million by 2033on July 29, 2024 at 10:44 pm
The Gastrointestinal stromal tumor (GIST) therapeutics market is expected to grow at a value of 6% CAGR in the forecast period 2023-2033. By end user, hospitals are expected to hold 45% of the market ...
- Bilateral Mastectomy Reduces Contralateral Breast Cancer Risk, but Not Mortalityon July 29, 2024 at 2:38 pm
Treating unilateral breast cancer with a bilateral mastectomy substantially reduced the risk of contralateral breast cancer compared with unilateral mastectomy or lumpectomy, yet not breast cancer ...
- New drug candidate blocks resistance to cancer therapieson July 29, 2024 at 11:53 am
A team of researchers at the University of Michigan Health Rogel Cancer Center has designed a molecule that impairs signaling mediated by two key drivers of cancer therapy resistance. The design and ...
- p53 in Cancer Therapy: The Impact of Mutations on the Genome Guardianon July 29, 2024 at 2:37 am
Important Note : All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves ...
- SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directorson July 28, 2024 at 11:30 pm
STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today ...
- Boehringer Ingelheim buys Nerio Therapeutics for $1.3Bon July 28, 2024 at 5:00 pm
“Securing the rights to Nerio Therapeutics’ novel checkpoint inhibitors creates a broad panel of exciting new cancer treatment combination opportunities,” said Paola Casarosa, member of the board of ...
- Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placementon July 26, 2024 at 7:02 pm
The Private Placement is subject to the final acceptance of the TSX-V and all securities issuable in connection with the Private Placement are subject to resale restrictions for a period of four ...
- Allarity Therapeutics Hit By SEC Notice Related Disclosures Of Once Lead Cancer Programon July 22, 2024 at 9:30 am
Allarity Therapeutics receives a Wells Notice from the SEC regarding disclosures about their FDA meetings for the New Drug Application of dovitinib.
- Actuate halves upcoming IPO to just $22M, scaling back clinical plans for cancer drugon July 22, 2024 at 1:54 am
Actuate Therapeutics was already keeping its planned IPO on the modest side, but the cancer-focused biotech has now lowered those expectations even further. | Actuate Therapeutics was already keeping ...
- Philippines Lung Cancer Therapeutics Market Assessment Understanding Demand and Supply Dynamicson July 17, 2024 at 3:36 pm
Report Ocean is proud to present a comprehensive analysis of the Philippines Lung Cancer Therapeutics market, offering a detailed examination of its various facets from 2018 to 2032. Our extensive ...
via Bing News